Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

David E. Cohn, Michael W. Sill, Joan L. Walker, David O'Malley, Christa I. Nagel, Teresa L. Rutledge, William Bradley, Debra L. Richardson, Katherine M. Moxley, Carol Aghajanian

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. Patients and methods Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80 mg/m2 intravenously days 1, 8, and 15 every 4 weeks) or the combination of paclitaxel (80 mg/m2 intravenously days 1, 8, and 15) plus reovirus 3 × 1010 TCID50/day intravenously on days 1–5, both every 4 weeks until disease progression or toxicity. The primary end point was PFS. The study was designed with 80% power for a one-sided alternative at a 10% level of significance to detect a reduction in the hazard by 37.5%. Results The study accrued 108 patients, 100 of whom were evaluable for toxicity. Median PFS was 4.3 months for paclitaxel and 4.4 months for paclitaxel plus reovirus (hazard ratio, 1.11; 90% two-sided CI, 0.78 to 1.59; one-sided P = 0.687). The proportion responding (overall response rate) to paclitaxel was 20% among 45 patients with measurable disease receiving paclitaxel alone, and 17.4% among the 46 patients treated with the combination. The asymptotic relative probability of responding was 0.87 (90% CI, 0.42 to 1.79). Severe adverse events were more common in the combination regimen than in paclitaxel arm for severe neutropenia (grade ≥ 4, 12% versus 0%), and severe respiratory adverse events (grade ≥ 3, 25% versus 2%). No deaths were considered treatment related. Conclusion The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation.

Original languageEnglish (US)
Pages (from-to)477-483
Number of pages7
JournalGynecologic Oncology
Volume146
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Paclitaxel
Neoplasms
Disease-Free Survival
Mammalian orthoreovirus 3
Neutropenia
Disease Progression
Therapeutics
Carcinoma

Keywords

  • Oncolytic virus
  • Paclitaxel
  • Recurrent ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer : An NRG Oncology/Gynecologic Oncology Group study. / Cohn, David E.; Sill, Michael W.; Walker, Joan L.; O'Malley, David; Nagel, Christa I.; Rutledge, Teresa L.; Bradley, William; Richardson, Debra L.; Moxley, Katherine M.; Aghajanian, Carol.

In: Gynecologic Oncology, Vol. 146, No. 3, 01.09.2017, p. 477-483.

Research output: Contribution to journalArticle

Cohn, David E. ; Sill, Michael W. ; Walker, Joan L. ; O'Malley, David ; Nagel, Christa I. ; Rutledge, Teresa L. ; Bradley, William ; Richardson, Debra L. ; Moxley, Katherine M. ; Aghajanian, Carol. / Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer : An NRG Oncology/Gynecologic Oncology Group study. In: Gynecologic Oncology. 2017 ; Vol. 146, No. 3. pp. 477-483.
@article{1dc57d33408347debb42c2431582d777,
title = "Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin{\circledR}) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study",
abstract = "Objective To assess whether the addition of oncolytic reovirus (Reolysin{\circledR}) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. Patients and methods Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80 mg/m2 intravenously days 1, 8, and 15 every 4 weeks) or the combination of paclitaxel (80 mg/m2 intravenously days 1, 8, and 15) plus reovirus 3 × 1010 TCID50/day intravenously on days 1–5, both every 4 weeks until disease progression or toxicity. The primary end point was PFS. The study was designed with 80{\%} power for a one-sided alternative at a 10{\%} level of significance to detect a reduction in the hazard by 37.5{\%}. Results The study accrued 108 patients, 100 of whom were evaluable for toxicity. Median PFS was 4.3 months for paclitaxel and 4.4 months for paclitaxel plus reovirus (hazard ratio, 1.11; 90{\%} two-sided CI, 0.78 to 1.59; one-sided P = 0.687). The proportion responding (overall response rate) to paclitaxel was 20{\%} among 45 patients with measurable disease receiving paclitaxel alone, and 17.4{\%} among the 46 patients treated with the combination. The asymptotic relative probability of responding was 0.87 (90{\%} CI, 0.42 to 1.79). Severe adverse events were more common in the combination regimen than in paclitaxel arm for severe neutropenia (grade ≥ 4, 12{\%} versus 0{\%}), and severe respiratory adverse events (grade ≥ 3, 25{\%} versus 2{\%}). No deaths were considered treatment related. Conclusion The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation.",
keywords = "Oncolytic virus, Paclitaxel, Recurrent ovarian cancer",
author = "Cohn, {David E.} and Sill, {Michael W.} and Walker, {Joan L.} and David O'Malley and Nagel, {Christa I.} and Rutledge, {Teresa L.} and William Bradley and Richardson, {Debra L.} and Moxley, {Katherine M.} and Carol Aghajanian",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.ygyno.2017.07.135",
language = "English (US)",
volume = "146",
pages = "477--483",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer

T2 - An NRG Oncology/Gynecologic Oncology Group study

AU - Cohn, David E.

AU - Sill, Michael W.

AU - Walker, Joan L.

AU - O'Malley, David

AU - Nagel, Christa I.

AU - Rutledge, Teresa L.

AU - Bradley, William

AU - Richardson, Debra L.

AU - Moxley, Katherine M.

AU - Aghajanian, Carol

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objective To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. Patients and methods Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80 mg/m2 intravenously days 1, 8, and 15 every 4 weeks) or the combination of paclitaxel (80 mg/m2 intravenously days 1, 8, and 15) plus reovirus 3 × 1010 TCID50/day intravenously on days 1–5, both every 4 weeks until disease progression or toxicity. The primary end point was PFS. The study was designed with 80% power for a one-sided alternative at a 10% level of significance to detect a reduction in the hazard by 37.5%. Results The study accrued 108 patients, 100 of whom were evaluable for toxicity. Median PFS was 4.3 months for paclitaxel and 4.4 months for paclitaxel plus reovirus (hazard ratio, 1.11; 90% two-sided CI, 0.78 to 1.59; one-sided P = 0.687). The proportion responding (overall response rate) to paclitaxel was 20% among 45 patients with measurable disease receiving paclitaxel alone, and 17.4% among the 46 patients treated with the combination. The asymptotic relative probability of responding was 0.87 (90% CI, 0.42 to 1.79). Severe adverse events were more common in the combination regimen than in paclitaxel arm for severe neutropenia (grade ≥ 4, 12% versus 0%), and severe respiratory adverse events (grade ≥ 3, 25% versus 2%). No deaths were considered treatment related. Conclusion The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation.

AB - Objective To assess whether the addition of oncolytic reovirus (Reolysin®) to weekly paclitaxel prolonged progression-free survival (PFS) in the treatment of women with recurrent or persistent ovarian, tubal or primary peritoneal cancer. Patients and methods Patients with recurrent or persistent epithelial ovarian, tubal, or peritoneal carcinoma, measurable or detectable disease, and three or fewer prior regimens were randomly assigned to paclitaxel (80 mg/m2 intravenously days 1, 8, and 15 every 4 weeks) or the combination of paclitaxel (80 mg/m2 intravenously days 1, 8, and 15) plus reovirus 3 × 1010 TCID50/day intravenously on days 1–5, both every 4 weeks until disease progression or toxicity. The primary end point was PFS. The study was designed with 80% power for a one-sided alternative at a 10% level of significance to detect a reduction in the hazard by 37.5%. Results The study accrued 108 patients, 100 of whom were evaluable for toxicity. Median PFS was 4.3 months for paclitaxel and 4.4 months for paclitaxel plus reovirus (hazard ratio, 1.11; 90% two-sided CI, 0.78 to 1.59; one-sided P = 0.687). The proportion responding (overall response rate) to paclitaxel was 20% among 45 patients with measurable disease receiving paclitaxel alone, and 17.4% among the 46 patients treated with the combination. The asymptotic relative probability of responding was 0.87 (90% CI, 0.42 to 1.79). Severe adverse events were more common in the combination regimen than in paclitaxel arm for severe neutropenia (grade ≥ 4, 12% versus 0%), and severe respiratory adverse events (grade ≥ 3, 25% versus 2%). No deaths were considered treatment related. Conclusion The addition of reovirus to weekly paclitaxel in the treatment of women with recurrent or persistent ovarian, tubal or peritoneal cancer did not sufficiently reduce the hazard of progression or death to warrant further investigation.

KW - Oncolytic virus

KW - Paclitaxel

KW - Recurrent ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85026308792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026308792&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.07.135

DO - 10.1016/j.ygyno.2017.07.135

M3 - Article

C2 - 28756871

AN - SCOPUS:85026308792

VL - 146

SP - 477

EP - 483

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -